Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1991-12-26
1995-04-18
Kepplinger, Esther M.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 74, 436506, 436518, 436811, B01N 33567
Patent
active
054078024
ABSTRACT:
Two subsets of Islet Cell Autoantibodies (ICA), termed restricted and non-restricted, have been identified. The expression of non-restricted ICA correlates with progression to type I diabetes, indicating that these individuals are at much greater risk than are individuals expressing restricted ICA. Differentiation between restricted or non-restricted ICA allows for more accurate prognosis of the development of type I diabetes. Restricted ICA react with beta cells of human and rat islets but not mouse, whereas non-restricted ICA react with humans rat and mouse islets. Restricted ICA can be substantially completely absorbed by incubation with glutamic acid decarboxylase (GAD), whereas non-restricted ICA are partially or not at all absorbed by GAD. Restricted ICA react in a Stiff-Man Syndrome fashion including staining GABAergic neurons in brain sections and western blots of brain extracts, whereas non-restricted ICA does not react with either brain sections nor with GAD antigen in western blots. Restricted ICA contains a higher titer of anti-GAD antibodies than does non-restricted ICA.
REFERENCES:
Vardi et al., Diabetologia, 34: 93-102 (1991).
Bonifacio, et al., The Lancet, 335: 147-149 (Jan. 20, 1990).
Riley, et al., N. Eng. J. Med., 323: 1167-1172 (Oct. 25, 1990).
Colman, P. G. et al., Diabetes, 37: 645-652 (May 1988).
Baekkeskov, S. et al., J. Clin. Invest., 79: 926-934 (Mar. 1987).
Gianani, R., et al., Diabetes 40 Suppl. 1; 224A. (Jun. 1991).
Ziegler, R., et al., Horm. Res. 33: 144-151 (1990).
Eisenbarth, G., Mount Sinai Journal of Medicine 58(4): 274-279 (Sep. 4, 1991).
Erlich, H. A., et al., Diabetes 40: 478-481 (Apr. 1991).
Ziegler, R., et al., Diabetes 40: 709-714 (Jun. 1990).
Kaufman, D. L. et al. (Jan. 1991) Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin-dependent Diabetes Mellitus J. Clin. Invest. 89: 283-292.
Cram, D. S. et al. (May 1991) Cloning And Partial Nucleotide Sequence Of Human Glutamic Acid Decarboxylase cDNA From Brain And Pancreatic Islets Biochem Biophys. Res. Comm. 176(3): 1239-1244.
Michelsen, B. K. et al. (Oct. 1991) Cloning, Characterization, and autoimmune recognition of rat islet glutamic acid decarboxylase in insulin-dependent diabetes mellitus Proc. Natl. Acad. Sci. USA 88:8754-8758.
Kaufman, D. L. et al. (1986) Two Forms of the .gamma.Aminobutyric Acid Synthetic Enzume Glutamate Decarboxylase Have Distinct Intraneuronal Distributions and Cofactor Interactions J. Neurochem. 56:720-723.
Baermier, H. et al., "Risk for Developing Type 1 Insulin-Dependent, Diabetes Mellitus and the Presence of Islets 64K Antibodies, " Abstract and full reference Diabetologia 34 (10), 1991, pp. 727-733.
Christgau, S. et al., "Pancreatic B Cells Express Two Autoantigenic Forms of Glutamic Acid Decarboxylase, a 65-kDa Hydrophilic Form and a 64-kDa Amphiphilic Form Which Can Be Both Membrane-bound and soluble", The Journal of Biological Chemistry, vol. 266, No. 31, Nov. 5, 1991, pp. 21257-21264.
Ziegler et al. Diabetes Care vol. 13 (1990) pp. 762-775.
Ziegler, et al., Diabetes, 38: 1320-1325 (1989).
Eisenbarth George S.
Gianani Roberto
Immulogic Pharmaceutical Corporation
Kepplinger Esther M.
Wortman Donna C.
LandOfFree
Method of accessing the risks of developing type I diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of accessing the risks of developing type I diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of accessing the risks of developing type I diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-66157